BRAF in metastatic colorectal cancer: the future starts now

被引：14

作者：

Orlandi, Armando ^{[1
]}

Calegari, Maria Alessandra ^{[1
]}

Inno, Alessandro ^{[2
]}

Berenato, Rosa ^{[3
]}

Caporale, Marta ^{[3
]}

Niger, Monica ^{[3
]}

Bossi, Ilaria ^{[3
]}

Di Bartolomeo, Maria ^{[3
]}

de Braud, Filippo ^{[3
]}

Pietrantonio, Filippo ^{[3
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dept Med Oncol, Rome, Italy

[2] Sacro Cuore Don Calabria Hosp, Med Oncol, Verona, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

来源：

PHARMACOGENOMICS | 2015年 / 16卷 / 18期

关键词：

BRAF; colorectal cancer; immunotherapy; target therapy; FOLFOXIRI PLUS BEVACIZUMAB; EGFR MONOCLONAL-ANTIBODIES; KRAS MUTATIONAL STATUS; COLON-CANCER; V600E MUTATION; MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; RAS MUTATIONS; POOR SURVIVAL; MAPK PATHWAY;

D O I：

10.2217/pgs.15.140

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BRAF mutations are detectable in about 5-15% of metastatic colorectal cancer (mCRC) patients and represent a clear negative prognostic factor. While in BRAF-mutated (BRAFmt) metastatic melanoma TKI target therapies (BRAF and MEK inhibitor), both alone or in combination, have shown significant efficacy, in BRAFmt CRC single-agent BRAF-inhibitors as well as chemotherapy seem to be ineffective. The critical role of EGFR in CRC and its multiple downstreaming pathways seem to be involved in this lack of response. In recent years, preclinical investigations and retrospective studies slowly increased our knowledge on BRAFmt CRC. This review analyses preclinical data and discusses several clinical trials in order to explore new therapeutic strategies targeting BRAFmt mCRC.

引用

页码：2069 / 2081

页数：13

共 50 条

[1] BRAF-mutated metastatic colorectal cancer between past and future
Cremolini, Chiara
Di Maio, Massimo
Petrelli, Fausto
Berenato, Rosa
Loupakis, Fotios
Pietrantonio, Filippo
BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1634 - 1635
[2] BRAF-mutated metastatic colorectal cancer between past and future
Chiara Cremolini
Massimo Di Maio
Fausto Petrelli
Rosa Berenato
Fotios Loupakis
Filippo Pietrantonio
British Journal of Cancer, 2015, 113 : 1634 - 1635
[3] The future starts now
Godwin, Dick
Resource: Engineering and Technology for Sustainable World, 2011, 18 (01):
[4] The future starts now
Platoni, Kara
MIT TECHNOLOGY REVIEW, 2024, 127 (05): : 42 - 49
[5] The future starts now
Dix, Juergen
Fisher, Michael
ANNALS OF MATHEMATICS AND ARTIFICIAL INTELLIGENCE, 2025,
[6] The future starts now!
Turner, Eurial
CELEBRATING MINORITY PROFESSIONALS IN FORESTRY AND NATURAL RESOURCES CONSERVATION: PROCEEDINGS OF THE SYMPOSIUM ON THE TENTH ANNIVERSARY OF THE 2 + 2 JOINT DEGREE PROGRAM IN FORESTRY AND NATURAL RESOURCES CONSERVATION, 2008, 106 : 31 - 33
[7] The Future Starts Now
Panza, Carol M.
PERFORMANCE IMPROVEMENT QUARTERLY, 2012, 25 (01) : 13 - 21
[8] Metastatic colorectal cancer. Modern therapy concepts now and in the future
Ettrich, T. J.
Seufferlein, T.
COLOPROCTOLOGY, 2016, 38 (05) : 307 - 313
[9] Metastatic colorectal cancer. Modern therapy concepts now and in the future
Ettrich, T. J.
Seufferlein, T.
ONKOLOGE, 2016, 22 (02): : 109 - 114
[10] BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
Li, Zi-Nan
Zhao, Lin
Yu, Li-Feng
Wei, Min-Jie
GASTROENTEROLOGY REPORT, 2020, 8 (03): : 192 - 205

← 1 2 3 4 5 →